These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand. Akawatcharangura P; Taechakraichana N; Osiri M Lupus; 2016 Apr; 25(4):436-44. PubMed ID: 26621134 [TBL] [Abstract][Full Text] [Related]
3. Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis. Giambalvo S; Garaffoni C; Silvagni E; Furini F; Rizzo R; Govoni M; Bortoluzzi A Autoimmun Rev; 2022 Apr; 21(4):103038. PubMed ID: 34995765 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Mayorga J; Alpízar-Rodríguez D; Prieto-Padilla J; Romero-Díaz J; Cravioto MC Lupus; 2016 Jun; 25(7):675-83. PubMed ID: 26678443 [TBL] [Abstract][Full Text] [Related]
5. Ovarian antibodies among SLE women with premature menopause after cyclophosphamide. Tsaliki M; Koelsch KA; Chambers A; Talsania M; Scofield RH; Chakravarty EF Int J Rheum Dis; 2021 Jan; 24(1):120-124. PubMed ID: 33300669 [TBL] [Abstract][Full Text] [Related]
6. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. McDermott EM; Powell RJ Ann Rheum Dis; 1996 Apr; 55(4):224-9. PubMed ID: 8733438 [TBL] [Abstract][Full Text] [Related]
7. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study. Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312 [TBL] [Abstract][Full Text] [Related]
9. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Manger K; Wildt L; Kalden JR; Manger B Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968 [TBL] [Abstract][Full Text] [Related]
10. Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy. Sen M; Kurl A; Khosroshahi A Lupus; 2021 Aug; 30(9):1509-1514. PubMed ID: 34053364 [TBL] [Abstract][Full Text] [Related]
11. Ovarian Insufficiency is Major Short-term Toxicity in Systemic Lupus Erythematosus Patients Treated with Cyclophosphamide. Singh G; Misra R; Aggarwal A J Assoc Physicians India; 2016 Feb; 64(2):28-31. PubMed ID: 27730777 [TBL] [Abstract][Full Text] [Related]
12. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup? Catoggio LJ; Soriano ER; Imamura PM; Wojdyla D; Jacobelli S; Massardo L; Chacón Díaz R; Guibert-Toledano M; Alvarellos A; Saurit V; Manni JA; Pascual-Ramos V; Silva de Sauza AW; Bonfa E; Tavares Brenol JC; Ramirez LA; Barile-Fabris LA; De La Torre IG; Alarcón GS; Pons-Estel BA; Lupus; 2015 Jul; 24(8):788-95. PubMed ID: 25504653 [TBL] [Abstract][Full Text] [Related]
13. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M Lupus; 2000; 9(6):401-5. PubMed ID: 10981642 [TBL] [Abstract][Full Text] [Related]
15. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Medeiros MM; Silveira VA; Menezes AP; Carvalho RC Braz J Med Biol Res; 2001 Dec; 34(12):1561-8. PubMed ID: 11717709 [TBL] [Abstract][Full Text] [Related]
16. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus. Mok CC; Chan PT; To CH Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647 [TBL] [Abstract][Full Text] [Related]
17. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Blumenfeld Z; Mischari O; Schultz N; Boulman N; Balbir-Gurman A Semin Arthritis Rheum; 2011 Dec; 41(3):346-52. PubMed ID: 21868068 [TBL] [Abstract][Full Text] [Related]
18. Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients. Tiseo BC; Bonfá E; Borba EF; Munhoz GA; Wood G; Srougi M; Silva CA; Cocuzza M Lupus; 2019 Jan; 28(1):59-65. PubMed ID: 30509155 [TBL] [Abstract][Full Text] [Related]
19. The prevalence and phenotypic characteristics of spontaneous premature ovarian failure: a general population registry-based study. Haller-Kikkatalo K; Uibo R; Kurg A; Salumets A Hum Reprod; 2015 May; 30(5):1229-38. PubMed ID: 25712230 [TBL] [Abstract][Full Text] [Related]
20. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]